Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

Status Recruiting

Clinical Trial Summary

The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood draw,12 months after their initial vaccination.

Clinical Trial Description

The investigators are studying an alternate dosing regimen of an approved drug (9vHPV vaccine) in the population for which it is approved. The vaccine is approved for individuals ages 9-45 years old and participants in this study will be 27-45 years of age. The purpose of the study is to examine the immune response of 2 doses of 9vHPV vaccine. The current recommendation is to administer the vaccine in 3 doses (administered at 0, 1-2 months and 6 months) to those 15-45 years of age, but only 2 doses (administered at 0 and 6 months) if the vaccine series is initiated before age 15. The investigators will conduct a randomized study to determine if 2 doses of elicit a similar immune response to that of a standard 3 dose series in individuals 27-45 years of age. Participants in the study group will receive 2 doses of at 0 and 6 months. Participants in the control group will receive 3 doses of 9vHPV vaccine at 0, 2 months, and 6 months. All participants (target accrual n=618) will have 5 mLs of blood drawn at 0, 1, 7, and 12 months. Following the 12-month blood draw, participants randomized to 2-doses will be offered the 3rd dose. Potential participants will be recruited through the University of Texas Medical Branch (UTMB) clinics and surrounding community, and will be screened for inclusion/exclusion criteria. Eligible patients will sign an informed written consent. At their baseline visit, participants will have their blood drawn, be randomized into either the study or control group, and receive their first dose of the HPV vaccine. All participants will receive compensation administered through a ClinCard following each of the 4 blood draws. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05672927
Study type	Interventional
Source	The University of Texas Medical Branch, Galveston
Contact	Abbey B Berenson, MD, PhD
Phone	409-772-2417
Email	abberens@utmb.edu
Status	Recruiting
Phase	Phase 4
Start date	January 18, 2023
Completion date	August 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04098744` - Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)	Phase 2
Completed	`NCT04083196` - A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years	Phase 1
Completed	`NCT04191967` - Thermocoagulation for Treatment of Precancerous Cervical Lesions	N/A
Withdrawn	`NCT04430907` - HPV Vaccine in Postpartum Women
Recruiting	`NCT02593968` - Yallaferon in Chinese Population	Phase 2
Completed	`NCT04711265` - Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
Completed	`NCT02263378` - A New Supplement for the Immune Response to HPV Infection	N/A
Completed	`NCT05234112` - Prevention and Screening Towards Elimination of Cervical Cancer	N/A
Completed	`NCT04590521` - HPV Vaccine Immunity in High-risk Women	Phase 4
Recruiting	`NCT05829629` - Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women	Phase 1
Recruiting	`NCT06052033` - Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection	N/A
Recruiting	`NCT05051852` - HPV Viral Load in Predicting the Prognosis of LSIL
Completed	`NCT04155294` - Re-Evaluation of Annual Cytology Using HPV Testing to Upgrade Prevention in Women Living With HIV
Completed	`NCT06177236` - Clinic or Self-Sampling for Cervical Cancer Screening	N/A
Active, not recruiting	`NCT04794660` - The Study for the "Cervical Cancer Screening and Treatment Algorithms Study Using HPV Testing in Africa"	Phase 3
Recruiting	`NCT05509413` - DEFLAGYN® Vaginal Gel and Spontaneous Remission and Regression of Unclear Cervical Smears and HPV High-risk Infections	N/A
Recruiting	`NCT06137950` - Interferon Alpha Therapy for Cervical CINI and HPV Infection	Phase 1
Recruiting	`NCT04171505` - Retrospective Cohort Study of the Effectiveness of the Prophylactic Vaccine Against the Human Papilloma Virus in the Prevention of Recurrence in Women Who Have Received an Excisional Therapy by HSIL / CIN.
Recruiting	`NCT05524025` - The SPOT-HPV Study
Recruiting	`NCT04998318` - 1:1 Comparison of the Pocket Colposcope in Kenya	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.